All Oncology News

PSMA response was associated with improved metastasis-free survival in oligometastatic castration-sensitive prostate cancer.

A medical team at AHN tested two courses of neoadjuvant immunotherapy for advanced gastroesophageal cancer — a relatively rare disease.

The FDA has granted accelerated approval to selpercatinib for pediatric patients with select RET-altered metastatic thyroid cancers or solid tumors.

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

The FDA granted priority review to an sBLA seeking the approval of pembrolizumab plus chemotherapy as frontline therapy in malignant pleural mesothelioma.

The European Commission approved nivolumab plus cisplatin and gemcitabine for first-line treatment in unresectable or metastatic urothelial carcinoma.

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

Treatment with nivolumab plus cabozantinib yielded responses in patients with non-clear cell renal cell carcinoma.

CT041 was safe and showcased early signals of antitumor activity in heavily pretreated patients with metastatic pancreatic cancer.

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

Sameer Patel, MD, FACS, of Fox Chase Cancer Center, was recently named Vice President of the Robert H. Ivy Society of Plastic Surgeons. 

Perioperative pembrolizumab plus chemotherapy improved survival vs preoperative chemotherapy in high-risk, early-stage, triple-negative breast cancer.

Dato-DXd elicited a clinically meaningful but not statistically significant improvement in overall survival in pretreated, advanced non–small cell lung cancer.

The FDA has received a new drug application for the use of TLX007-CDx in the preparation of PSMA PET imaging of prostate cancer.

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

From barely escaping a life under communism in a Russia-occupied Latvia to overcoming a family health crisis, Robert F. Ozols, MD, PhD, knows a thing or two about beating the odds.

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

Positive PD-L1 expression was associated with worse survival in metastatic papillary renal cell carcinoma.

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.

David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

Ribociclib plus endocrine therapy bested combination chemotherapy in terms of progression-free survival in HR-positive, HER2-negative advanced breast cancer.

Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.

Eating more fruits, nuts and vegetables each day – along with fewer animal products – is associated with a nearly 50% reduction in the risk of prostate cancer progression.